Claims for Patent: 8,486,941

Summary for Patent: 8,486,941

Title:	Phenyl amino pyrimidine compounds and uses thereof
Abstract:	The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.
Inventor(s):	Burns Christopher John, Donohue Andrew Craig, Feutrill John Thomas, Nguyen Thao Lien Thi, Wilks Andrew Frederick, Zeng Jun
Assignee:	YM Biosciences Australia Pty Ltd
Application Number:	US12530610
Patent Claims:	2. The compound of which is a hydrochloride salt of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide.3. The compound of which is N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide.5. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable carrier.6. An implant which comprises the compound of .7. A pharmaceutical composition comprising the compound of in a pharmaceutically acceptable carrier.8. An implant which comprises the compound of .9. A method for the treatment of a disease associated with Janus Kinase (JAK) which comprises administering to a subject in need an effective amount of the compound of or a pharmaceutical composition thereof claim 1 , wherein the disease is a myeloproliferative disease.10. The method of wherein the myeloproliferative disease is myelofibrosis claim 9 , polycythemia vera (PV) and essential thrombocythemia (ET).11. The method of wherein the myeloproliferative disease is myelofibrosis.12. A method for the treatment of a disease associated with Janus Kinase (JAK) which comprises administering to a subject in need an effective amount of the compound of or a pharmaceutical composition thereof claim 4 , wherein the disease is a myeloproliferative disease.13. The method of wherein the myeloproliferative disease is selected from the group consisting of polycythemia vera (PV) claim 12 , myelofibrosis claim 12 , thrombocythemia claim 12 , essential thrombocythemia (ET) claim 12 , idiopathic myelofibrosis claim 12 , chronic myelogenous leukemia claim 12 , systemic mastocystosis (SM) claim 12 , chronic neutrophilic leukemia (CNL) claim 12 , myelodisplastic syndrome (MDS) and systemic mast cell disease (SMCD).14. The method of wherein the myeloproliferative disease is myelofibrosis claim 13 , polycythemia vera (PV) and essential thrombocythemia (ET).15. The method of wherein the myeloproliferative disease is myelofibrosis.16. A method of inhibiting a JAK in a cell comprising contacting the cell with the compound of .17. A method of inhibiting a JAK in a cell comprising contacting the cell with the compound of .